Vancomycin use in a hospital with high prevalence of methicillin-resistant staphylococcus aureus: Comparison with hospital infection control practices advisory committe guidelines (HICPAC)

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 1, 2007, Pages 53-56

  De Melo, Daniela O ^a,c   Sasaki, Marli ^b   Grinbawa, Renato Satovachi ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Servidor Publico Estadual Hospital   (Brazil)

^c NONE   (Brazil)

Author keywords

Antimicrobial use; Guidelines; Infection; Vancomycin

Indexed keywords

BETA LACTAM ANTIBIOTIC; VANCOMYCIN;

ADULT; ADVISORY COMMITTEE; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD CULTURE; CATHETER INFECTION; CHILD; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG HYPERSENSITIVITY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; SEPSIS; SURGICAL INFECTION; TERTIARY HEALTH CARE;

EID: 34347383611     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702007000100014     Document Type: Article

References (44)

1. Fridkin S.K., Steward C.D., Edwards J.R., et al. Surveillance of antimicrobial use in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999;29:245-52.
2. Mutnick A.H., Rhomberg P.T., Sader H.S., Jones R.N. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
3. Edmond M.B., Ober J.F., Dawson J.D., et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
4. Cieslak P.R., Strausbaugh L.J., Fleming D.W., Ling J.M. Vancomycin in Oregon: who's using it and why. Infect. Control Hosp. Epidemiol 1999;20(8):557-60.
5. Grayson M.L., Grabsch E.A., Johnson P.D., et al. Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med J Aust 1999;171:133-6.
6. Hendrix C.W., Hammond J.M.J., Swoboda S.M., et al. Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Ann Surg 2001; 233:259-65.
7. Price C.S., Paule S., Noskin G.A., Peterson L.R. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003;37:921-8.
8. Montecalvo M.A., Jarvis W.R., Uman J., et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269-72.
9. Ostrowsky B.E., Trick W.E., Sohn A.H., et al. Control of vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427-33.
10. Hachem R., Graviss L., Hanna H., et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004;25:391-4.
11. Centers of Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance - Recommendations Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(RR12):1-13.
12. Morgan S.A., Brennan J.P., Fishman O.N. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacotherapy 1997;31:1-970-3.
13. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report: data summary from October 1986-April 1998, issued June 1998. Am J Infect Control 1998;26:522-33.
14. Zanella R.C., Valdetaro F., Lovgren M., et al. First confirmed case of a vancomycin-resistant Enterococcus faecium with vanA phenotype from Brazil: isolation from a meningitis case in Sao Paulo. Microb Drug Resist 1999;5(2):159-62.
15. Cereda R.F., Gales A.C., Silbert S., et al. Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. Infect. Control Hosp. Epidemiol 2002; 23(1):19-22.
16. Lodise T.P., Mckinnon P.S., Tam V.H., Rybak M.J. Clinical outcomes for patients with bactermia caused by vancomycin resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-9.
17. Carmeli Y., Eliopoulos G., Mozaffari E., Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-8.
18. Noble W.C., Virani Z., Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. Microbiol Lett 1992;72:195-8.
19. Warren D.K., Nitin A., Hill C., et al. Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control and Hosp Epidemiol 2004;25:99-104.
20. Thomas R.A., Cieslak R.P., Straugsbaugh J.L., Fleming W.D. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: A population- based assessment. Infect Control Hosp Epidemiol 2002; 23:683-8.
21. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strengh with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
22. Rotun S.S., McMath V., Schoonmaker D., et al.Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
23. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340:493-501.
24. Centers for Disease Control and Prevention.Staphylococcus aureus with reduced susceptibily to vancomycin: Illinois, 1999. MMWR 2000;48:1165-7.
25. Centers for Disease Control and Prevention. Public Health dispatch: Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR 2002;51(40):902-3.
26. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002;51:565-7.
27. Camargo I.L., Zanella R.C., Brandileone M.C., et al. Occurrence of insertion sequences within the genomes and Tn 1546-like elements of glycopeptide-resistant enterococci isolated in Brazil, and identification of a novel element, ISEfa5. Int J Med Microbiol 2005;294(8):513-9.
28. Palazzo I.C., Araujo M.L., Darini A.L. First report of vancomycin resistant staphylococci isolated from healthy carriers in Brazil. J Clin Microbiol 2005;43(1):179-85.
29. Kluytmans-Vandenbergh M.F., Kluytmans J.A. Community acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 2006;12(Suppl 1):9-15.
30. Lautenbach E., Biulker W.B., Brennan P.J. Enterococcal bacterimia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-23.
31. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
32. Norris A.H., Reilly J.P., Edelstein P.H., et al. Chloranphenicol for the treament of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
33. Salemi C., Becker L., Morrisey R., Warmington J. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Clinical Performance and Quality Health Care 1998; 32:12-6.
34. Evans M.E., Kortas K.J. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee Guidelines. Infect Control Hosp Epidemiol 1996;17:356-9.
35. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-9.
36. Rehm S.J. Two new treatment options for infections due to drugresistant Gram-positive cocci. Cleve Clin Med 2002;69:397-413.
37. Singer M.V., Haft R., Barlan T., et al. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248-53.
38. Schumacher G.E. Therapeutic drug monitoring. Connecticut: Appleton & Lange, 1995:684.
39. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20.
40. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-94.
41. Romer-Vivas J., Rubio M., Fernandez C., Picazo J.J. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417-23.
42. Leibovici L., Shraga I., Drucker M., et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-86.
43. Solomkin J.S., Bjornson H.S., Cainzos M., et al. A consensus statement on empiric therapy for suspected Gram-positive infections. The Am J of Surgery 2004;187:134-45.
44. Van Houten N.A., Uiterwaal C.S.P.M., Heesen G.J.M., et al. Does the empiric use of vancomycin in pediatrics increase the risk for Gram-negative bacteremia? Pediatr Infect Dis J 2001;20:171-7.